Pure Global
NCT06237777

A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients

An Open, Dose-escalation Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients in China
Wang Min·Phase 1·ClinicalTrials.gov·geneticRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetic Macular Edema
Drug/Device/Intervention
SKG0106 intravitreal injection dose level 1, 2 or 3
Study type
Interventional
Intervention type
genetic
Sponsor & location
Primary sponsor
Wang Min
Funder
Eye & ENT Hospital of Fudan University
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 01, 2024
End date
Jan 01, 2026
Enrollment
18 participants
Primary outcome

Type, severity, and incidence of ocular and systemic AEs,Incidence of DLT

Summary

This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106
 intravitreal injection in diabetic macular edema (DME) patients.

ICD-10 classifications
Diabetic retinopathyOther specified diabetes mellitus with ophthalmic complicationsUnspecified diabetes mellitus with ophthalmic complicationsDiabetic cataractType 2 diabetes mellitus with ophthalmic complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06237777
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06237777 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wang Min and is currently Recruiting. The study focuses on Diabetic Macular Edema. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.